GH Research (NASDAQ:GHRS) Price Target Cut to $28.00 by Analysts at Canaccord Genuity Group

GH Research (NASDAQ:GHRS) had its target price lowered by Canaccord Genuity Group from $31.00 to $28.00 in a report issued on Monday,Benzinga reports. The firm currently has a buy rating on the stock.

Several other research firms also recently weighed in on GHRS. HC Wainwright restated a “buy” rating and set a $40.00 target price on shares of GH Research in a report on Thursday, September 5th. JMP Securities reaffirmed a “market outperform” rating and set a $39.00 price target on shares of GH Research in a research note on Wednesday, September 4th.

GH Research Stock Performance

Shares of GH Research stock opened at $9.47 on Monday. The company has a market cap of $492.72 million, a P/E ratio of -11.99 and a beta of 0.74. GH Research has a one year low of $5.05 and a one year high of $14.99. The firm has a fifty day moving average of $7.78 and a two-hundred day moving average of $10.34.

GH Research (NASDAQ:GHRS) last announced its quarterly earnings results on Tuesday, September 3rd. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.03. As a group, equities analysts predict that GH Research will post -0.85 earnings per share for the current year.

Institutional Investors Weigh In On GH Research

An institutional investor recently raised its position in GH Research stock. RA Capital Management L.P. boosted its holdings in GH Research PLC (NASDAQ:GHRS) by 1.3% during the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 6,686,689 shares of the company’s stock after buying an additional 85,000 shares during the period. RA Capital Management L.P. owned approximately 12.85% of GH Research worth $44,734,000 at the end of the most recent reporting period. Institutional investors own 56.90% of the company’s stock.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).